4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice

FASEB Journal

Volumn 25, Issue 1, 2011, Pages 290-300

  Wool, Geoffrey D ^a   Cabana, Veneracion G ^a   Lukens, John ^a   Shaw, Peter X ^b   Binder, Christoph J ^c,d   Witztum, Joseph L ^b   Reardon, Catherine A ^a   Getz, Godfrey S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ApoA I; E06 T15; Innate immunity; Mimetic; Oxidation

Indexed keywords

4F PEPTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; EPITOPE; IMMUNOGLOBULIN M ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRO PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; INNATE IMMUNITY; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

AGE FACTORS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL, LDL; EPITOPES; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; ORGAN SIZE; PEPTIDES; SERUM AMYLOID A PROTEIN; SPLEEN;

MUS;

EID: 79251573524     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-165670     Document Type: Article

References (40)

1. Kontush, A., and Chapman, M. J. (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342-374
2. Duffy, D., and Rader, D. J. (2009) Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6, 455-463
3. Shao, B., and Heinecke, J. W. (2009) HDL, lipid peroxidation, and atherosclerosis. J. Lipid Res. 50, 599-601
4. Rader, D. J., Alexander, E .T., Weibel, G. L., Billheimer, J., and Rothblat, G. H. (2009). The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl.), S189-S194
5. Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S., Hough, G., Grijalva, V. R., Yu, N., Ansell, B. J., Datta, G., Garber, D. W., and Fogelman, A. M. (2005) Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25, 1325-1331
6. Getz, G. S., Wool, G. D., and Reardon, C. A. (2009) Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr. Opin. Lipidol. 20, 171-175
7. Navab, M., Shechter, I., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2010) Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 30, 164-168
8. Wool, G. D., Reardon, C. A., and Getz, G. S. (2008) Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. J. Lipid Res. 49, 1268-1283
9. Wool, G. D., Vaisar, T., Reardon, C. A., and Getz, G. S. (2009) An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50, 1889-1900
10. Van Lenten, B. J., Wagner, A. C., Jung, C. L., Ruchala, P., Waring, A. J., Lehrer, R. I., Watson, A. D., Hama, S., Navab, M., Anantharamaiah, G. M., and Fogelman, A. M. (2008) Antiinflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49, 2302-2311
11. Glass, C. K., and Witztum, J. L. (2001) Atherosclerosis: the road ahead. Cell 104, 503-516
12. Carnemolla, R., Ren, X., Biswas, T. K., Meredith, S. C., Reardon, C. A., Wang, J., and Getz, G. S. (2008) The specific amino acid sequence between helices 7 and 8 influences the binding specificity of human apolipoprotein A-I for high density lipoprotein (HDL) subclasses: a potential for HDL preferential generation. J. Biol. Chem. 283, 15779-15788
13. Navab, M., Anantharamaiah, G. M., Hama, S., Garber, D. W., Chaddha, M., Hough, G., Lallone, R., and Fogelman, A. M. (2002) Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290-292
14. Garber, D. W., Datta, G., Chaddha, M., Palgunachari, M. N., Hama, S. Y., Navab, M., Fogelman, A. M., Segrest, J. P., and Anantharamaiah, G. M. (2001) A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42, 545-552
15. Li, X., Chyu, K. Y., Faria Neto, J. R., Yano, J., Nathwani, N., Ferreira, C., Dimayuga, P. C., Cercek, B., Kaul, S., and Shah, P. K. (2004) Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110, 1701-1705
16. Van Lenten, B. J., Wagner, A. C., Navab, M., Anantharamaiah, G. M., Hama, S., Reddy, S. T., and Fogelman, A. M. (2007) Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterolfed rabbits. J. Lipid Res. 48, 2344-2353
17. Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., and Rader, D. J. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49, 1344-1352
18. Reardon, C. A., Blachowicz, L., White, T., Cabana, V., Wang, Y., Lukens, J., Bluestone, J., and Getz, G. S. (2001) Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 1011-1016
19. Ou, J., Wang, J., Xu, H., Ou, Z., Sorci-Thomas, M. G., Jones, D. W., Signorino, P., Densmore, J. C., Kaul, S., Oldham, K. T., and Pritchard Jr., K.A. (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ. Res. 97, 1190-1197
20. VanderLaan, P. A., Reardon, C. A., Sagiv, Y., Blachowicz, L., Lukens, J., Nissenbaum, M., Wang, C.-R., and Getz, G. S. (2007) Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am. J. Pathol. 170, 1100-1107
21. Chou, M. Y., Fogelstrand, L., Hartvigsen, K., Hansen, L. F., Woelkers, D., Shaw, P. X., Choi, J., Perkmann, T., Bäckhed, F., Miller, Y. I., Hörkkö, S., Corr, M., Witztum, J. L., and Binder, C. J. (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Invest. 119, 1335-1349
22. Chou, M. Y., Hartvigsen, K., Hansen, L. F., Fogelstrand, L., Shaw, P. X., Boullier, A., Binder, C. J., and Witztum, J. L. (2008) Oxidation-specific epitopes are important targets of innate immunity. J. Intern. Med. 26 3, 479-488
23. Shaw, P. X., Hörkkö, S., Chang, M. K., Curtiss, L. K., Palinski, W., Silverman, G. J., and Witztum, J. L. (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105, 1731-1740
24. VanderLaan, P. A., Reardon, C. A., and Getz, G. S. (2004) Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler. Thomb. Vasc. Biol. 24, 12-22
25. Navab, M., Anantharamaiah, G. M., Hama, S., Hough, G., Reddy, S. T., Frank, J. S., Garber, D. W., Handattu, S., and Fogelman, A. M. (2005) D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 1426-1432
26. Stocker, R., and Keaney Jr., J.F. (2004) Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381-1478
27. Binder, C. J., Hartvigsen, K., Chang, M. K., Miller, M., Broide, D., Palinski, W., Curtiss, L. K., Corr, M., and Witztum, J. L. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114, 427-437
28. Friedman, P., Hörkkö, S., Steinberg, D., Witztum, J. L., and Dennis, E. A. (2002) Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277, 7010-7020
29. Tsimikas, S., Palinski, W., and Witztum, J. L. (2001) Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 95-100
30. Palinski, W., Miller, E., and Witztum, J. L. (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 92, 821-825
31. Caligiuri, G., Khallou-Laschet, J., Vandaele, M., Gaston, A. T., Delignat, S., Mandet, C., Kohler, H. V., Kaveri, S. V., and Nicoletti, A. (2007) Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50, 540-546
32. Navab, M., Hama, S. Y., Cooke, C. J., Anantharamaiah, G. M., Chaddha, M., Jin, L., Subbanagounder, G., Faull, K. F., Reddy, S. T., Miller, N. E., and Fogelman, A. M. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41, 1481-1494
33. Salio, M., Silk, J. D., and Cerundolo, V. (2010) Recent advances in processing and presentation of CD1 bound lipid antigens. Curr. Opin. Immunol. 22, 81-88
34. Barral, P., Eckl-Dorna, J., Harwood, N. E., De Santo, C., Salio, M., Illarionov, P., Besra, G. S., Cerundolo, V., and Batista, F. D. (2008) B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc. Natl. Acad. Sci. U. S. A. 105, 8345-8350
35. Danner, D., and Leder, P. (1985) Role of an RNA cleavage/poly(A) addition site in the production of membrane-bound and secreted IgM mRNA. Proc. Natl. Acad. Sci. U. S. A. 82, 8658-8662 (Pubitemid 16105122)
36. Ross, D. A., Wilson, M. R., Miller, N. W., Clem, L. W., and Warr, G. W. (1998) Evolutionary variation of immunoglobulin mu heavy chain RNA processing pathways: origins, effects, and implications. Immunol. Rev. 166, 143-151
37. Binder, C. J., Hörkkö, S., Dewan, A., Chang, M. K., Kieu, E. P., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., and Silverman, G. J. (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9, 736-743
38. Nanjee, M. N., Cooke, C. J., Garvin, R., Semeria, F., Lewis, G., Olszewski, W. L., and Miller, N. E. (2001) Intravenous apoA-I/ lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. 42, 1586-1593
39. Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S., Hough, G., Grijalva, V. R., Wagner, A. C., Frank, J. S., Datta, G., Garber, D., and Fogelman, A. M. (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109, 3215-3220
40. Cabana, V. G., Lukens, J. R., Rice, K. S., Hawkins, T. J., and Getz, G. S. (1996) HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J. Lipid Res. 37, 2662-2674